NanoViricides, Inc. (NNVC): A typical nanoviricides drug is designed like a chemical missile. It has a number of recognition "ligands" on its surface, that are specific to a single type of virus, say HIV. They are like the GPS on a directed missile. They will identify the enemy and attach to specific "landing sites" on the enemy target. The nanoviricides drug, after landing, spreads itself all over the virus particle, and thus completely neutralizes and disables the virus particle from binding to its target, a human cell.
Website: nanoviricides.com
Patents: Solubilization and Targeted Delivery of Drugs with Selfassembling Amphiphilic PolymersTargets - May 10, 2012
EUGENE SEYMOUR, MD, MPH
Chief Executive Officer
NANOVIRICIDES, INC
- The plant should be ready for occupancy in roughly a year or so - May 2013
- The tox studies should be done before that
- We can go into humans in certain countries as soon as the tox studies are done and enough drug material is made in our laboratory to do the trials
- The plant should be ready to produce necessary materials for human trials in the US in approximately 18 months - November 2013
- We will file for the IND after we occupy the plant and FDA approval for US trials will be contingent on getting three consistent batches produced in the new plant - October 2013(?)
- If everything goes according to plan, I feel that we will hit the 2013-2014 flu season in the US with our trials and with some luck, the 2012-2013 season outside the US - March/April 2013
cGMP facility: 18,000 square foot building on a 4 acre lot at 1 Controls Drive in Shelton Connecticut enabling future expansion of operations.
Google Maps: is.gd
Oral administration:
Antibody response with Oral administration was stronger than that with IV administration. |
